Kornimate/medical-research-clean huggingface dataset:
mechanisms of cognitive change

Conditions: Psychosis

Summary: this study will determine whether targeted cognitive training, a low-cost and low-risk commercial cognitive remediation therapy, directly impacts therapeutic targets as well as secondary outcomes in college undergraduates. the active intervention will be compared to an active control condition (computer games). participants will also attend csu tilt (the institute for teaching and learning) academic workshops.

the primary goal of this project is to investigate whether commercial cognitive remediation therapy improves cognitive functioning in college undergraduates. the secondary goal is to investigate neurophysiological, cognitive, and psychosocial mechanisms of change. the investigators will compare cognitive remediation therapy to computer games. the active control condition will allow the investigators to determine whether targeted cognitive training, as an adjunct to academic skills training provided by csu tilt, provides significant improvement over computer games alone (which is also thought to provide some value as "brain training"). participants who agree to enroll in the study will be randomized to one of two intervention arms: cognitive remediation (cr) or active control (ac). in the cr arm, participants will complete 20 hours of targeted cognitive training, in 30-min session, 5 days per week, over 8 weeks. the ac arm will follow the same schedule, except that participants will complete video games (e.g., pong). all participants will repeat assessments at randomly determined midpoint, as well as after the 8 weeks of training have been completed.

Eligibility criteria:
inclusion criteria: * college undergraduate; * english fluency, and the ability to complete study requirements. exclusion criteria: * college seniors (i.e., students with more than 89 credits at csu); * students who are concurrently enrolled in another study investigating the efficacy or effectiveness of novel learning or cognitive development techniques (not including tutoring or other existing programs available to csu undergraduates); * participants less than age 15.
effectiveness of modified integrated colorectal cancer screening system in saudi arabia

Conditions: Colorectal Cancer; Colorectal Neoplasms

Summary: in order to encourage the population at risk to participate in colorectal cancer screening, this clustered trial intends to determine the efficacy of specific messages(nudge), single fit testing, and the primary care physician's clinical judgment on referral to colonoscopy. it primarily seeks to provide answers to the following questions: how effective is the modified integrated crc screening system (micrcss) for individuals with average colorectal cancer risk? based on the percentage of individuals who had crc screening, registered for the follow-up, and were discovered to have precancerous crc issues a year after the program's start, as contrasted to individuals receiving standard medical care? all public government entities in the hail region will be contacted with invitations to participate in the study (outreach). the organization

introduction: incidence of colorectal cancer (crc), which starts in the innermost lining mucosa of the colon or rectum, is third (10.2%) in the globe behind lung and breast cancers (11,6%), according to the global cancer observatory (gco) 2018. according to a 2010 research, saudi arabia had an incidence of 10.4/100,000; regrettably, the incidence among young age groups is greater than that in countries with high incidence. the majority of colorectal malignancies (crcs) are first identified as polyps, which are small benign growths or projections seen inside the lumen of the colon. if a polyp is larger than 1 cm, if there are more than two polyps present, or if dysplasia is seen after the polyp is removed, the polyp is considered to be precancerous. precancerous adenomas, hyperplastic polyps, or inflammatory polyps

Eligibility criteria:
inclusion criteria: * age 40 -75 exclusion criteria: * sever ill patient
bone health and microbiome in persons with type 1 diabetes

Conditions: Type1diabetes

Summary: it is well-established that persons with type 1 diabetes (t1d) are at an increased risk for morbidity and mortality related to bone fracture due to poor bone health, however we do not fully understand the mechanism behind the increased fracture risk. we are examining bone health and the microbiome in adolescents and young adults with type 1 diabetes to better understand the reasons behind this increased risk.

this pilot study aims to look at measures of bone health, the gut microbiome and measures of glycemia/glycemic variability in those with preclinical and clinical diabetes. our primary and secondary outcomes are to characterize these variables, with our long term objectives to better understand the natural history of bone health in t1d, help characterize the etiology of worse bone health in those with t1d, and try to identify potential time periods for intervention.

Eligibility criteria:
inclusion criteria: - willing and able to comply with study protocol for participants with type 1 diabetes (t1d): - t1d diagnosed clinically by an endocrinologist as documented in medical records. exclusion criteria: * use of oral or parenteral antibiotics within 3 months * use of probiotics/prebiotics/synbiotics within 3 months of enrollment; persons who eat yogurt will be asked to stop for 30 days prior to stool collection * use of medications that will affect bone, including glucocorticoids, bisphosphonates * chronic medications (other than insulin for those with t1d or a stable dose of thyroid hormone) * uncontrolled chronic gastrointestinal disease including celiac disease (persons with t1d will be screened for celiac disease with a tissue transglutaminase antibody (ttg)/immunoglobulin a (iga) if not done in prior 2 years) * known genetic syndrome that predisposes the participant to fracture (such as osteogenesis imperfect) or skeletal dysplasia that would affect skeletal assessment (such as hypochondroplasia) * pregnancy * any other condition that in the opinion of the investigator would jeopardize the safety or rights of the subject participating in the study or would make it unlikely the subject could complete the study additional exclusion criteria for healthy controls: * presence of any diabetes autoantibody * presence of any type of diabetes or hyperglycemia (hba1c≥5.7%)
study of accurate diagnosis and treatment of peutz-jeghers syndrome

Conditions: Peutz-Jeghers Syndrome

Summary: the mutation of stk11 has been regcognized to be the major cause of peutz-jeghers syndrome (pjs).the aim of this study was to confirm the mutation rate of gene associated with gastrointestinal malignancies,including stk11, apc,pms1,et al. furtherly, the investigators analyze the association of stk11 with gut microbiota.

all patients diagnosed as pjs were enrolled and accepted second generation gene sequencing with their blood specimens. then all patients allocated into gene mutation group and no gene mutation group according to if the cases accompany with gene mutation of stk11.also, health persons were enrolled and a case controlled study will be carried out.all patients and health persons accepted 16s rrna sequencing with their feces specimens.

Eligibility criteria:
inclusion criteria: 1. subject with ages from 18-70 years old. 2. subject diagnosed with peutz-jeughers syndrome. 3. subject without hypertension, diabetes and other gastrointestinal diseases. 4. the consent form has been signed. exclusion criteria: 1. subject is younger than 18 years or older than 70 years. 2. subject with hypertension,diabetes and other gastrointestinal diseases. 3. subject taken or adminstered medicine associated with digestive function during latest 1 month. 4. pregnant women.

Keywords: second generation gene sequencing, gut microbiota, gastrointestinal polyp syndrome
the effect of book reading on comfort, hope, anxiety and vital signs of intensive care unit patients

Conditions: Hope; Comfort; Anxiety; Vital Signs

Summary: this study was planned to investigate the effect of reading aloud books on comfort, hope, anxiety and vital signs in patients hospitalized in intensive care unit. this study was designed as a randomized controlled clinical trial. data will be collected by using the descriptive characteristics questionnaire, general comfort scale, dispositional hope scale, state-trait anxiety inventory, and the vital signs monitoring form.

this study was planned to investigate the effect of reading aloud books on comfort, hope, anxiety and vital signs in patients hospitalized in intensive care unit. this study was designed as a randomized controlled clinical trial. data will be collected by using the descriptive characteristics questionnaire, general comfort scale, dispositional hope scale, state-trait anxiety inventory, and the vital signs monitoring form. individuals in the intervention group will be read a storybook for 3 nights in the intensive care unit. the control group will not be subjected to any practice other than the routine practices of the clinic.

Eligibility criteria:
inclusion criteria: 1. over 18 years of age, 2. stable clinical condition after intensive care unit admission, 3. have no physical or mental impairment in answering the questions, 4. no verbal communication disability (hearing and speech), 5. no diagnosed psychiatric disorder, 6. with a glasgow coma scale score of 15, 7. not receiving sedation for at least 12 hours, 8. will be hospitalized for at least 3 days from the time of enrollment in the study, 9. individuals who agree to participate in the study will be included in the study. exclusion criteria: 1. people with hearing or vision problems, 2. intubated, 3. any diagnosed neurological or psychological disorder, 4. transferred to another unit or exitus before the specified period, 5. individuals who do not agree to participate in the study will not be included in the study.
open-label extension study of the phase 3 vrx-ret-e22-301 double-blind trial

Conditions: Epilepsy

Summary: the purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the vrx-ret-e22-301 double-blind study. the efficacy of long-term treatment with retigabine and patient quality of life will also be assessed.

this phase 3 trial is an open-label extension study of the placebo-controlled, double-blind vrx-ret-e22-301 trial. patients who have completed the vrx-ret-e22-301 trial and who meet inclusion and exclusion criteria will be treated with 600-1200 mg/day of retigabine as an adjunct therapy to their current antiepileptic drugs (aeds) or vagal nerve stimulation. treatment will be continued until retigabine is commercially available, or until the program is discontinued. patients will be recruited from 45-50 sites in the united states, canada, mexico, brazil, and argentina. the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures will be evaluated. in addition, the efficacy of long-term treatment with retigabine and patient quality of life will be assessed.

Eligibility criteria:
inclusion criteria: * patient has successfully completed the maintenance and transition phases of study vrx-ret-e22-301 for the treatment of partial-onset seizures * patient is expected to benefit from participation in the study in the opinion of the investigator. exclusion criteria: * patient meets any of the withdrawal criteria in the previous vrx-ret-e22-301 study or is experiencing an ongoing serious adverse event. * patient is receiving any investigational drug or using any experimental device in addition to retigabine for treatment of epilepsy or any other medical condition. * patient has any other condition that would prevent compliance with the study procedures or proper reporting of adverse events.

Keywords: epilepsy partial seizures potassium channels anticonvulsant complex partial seizures epilepsies, partial rtg115098
the tolerability, pharmacokinetics and pharmacodynamics study of hec74647 in hcv-infected subjects

Conditions: Chronic Hepatitis C

Summary: the goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity of hec74647 in hcv treatment naïve subjects with genotypes 1-6.

all subjects will be receive qd doses of hec74647 or the matching placebo for 3 days to assess the the tolerability, pharmacokinetics and antiviral activity at specified time-points during the study.all subjects also will be monitored for up to 8 days post-dose to determine the persistence of viral mutations.

Eligibility criteria:
inclusion criteria: * able to comprehend and sign the icf voluntarily prior to initiate the study; * able to complete the study according to the protocol; * agree to use protocol defined precautions against pregnancy * body weight of male and female subject should be ≥50 kg and ≥45 kg respectively; body mass index (bmi) is between 18 and 30 kg/m2, inclusive; * hcv treatment-naïve adult subjects with gt1-6 hcv infection * hcv rna level ≥ 5 log10 iu/ml at screening * fibroscan score within 6 months≤12.5 kpa or liver biopsy results within 12 months proved non-cirrhosis exclusion criteria: * smokers, who smoke more than 5 cigarettes/day within 3 months before the study; * drink frequently, namely alcohol consumption are 14 units per week (1 unit = 285 ml of beer, or 25 ml of strong wine, or 100 ml of grape wine); * donated blood or massive blood loss within 3 months before screening (\>450 ml）; * have any disease that increases the risk of bleeding, such as acute gastritis or stomach and duodenal ulcers; * have taken any prescription drug, over-the-counter drug, vitamin product or herbal medicine within 14 days prior to screening; * have taken any drug that inhibit gastric acid secretion, such as h2 receptor antagonist famotidine and proton pump inhibitor omeprazole; * have participated in any clinical trial or taken any study drug within 3 months before dosing; * positive test result of hbv,hiv or syphilis; * solid organ transplanters
cold knife conization with and without lateral hemostatic sutures

Conditions: Cervical Intraepithelial Neoplasia; Cervix Neoplasms

Summary: the treatment of high grade cervical intraepithelial neoplasia (cin) 2, 3 is defined according to the colposcopic evaluation of the patient. in case colposcopy findings are satisfactory (visible squamocolumnar junction), both ablative and excisional methods are adequate. in the middle of the 20th century, lateral hemostatic sutures were added to the cold knife conization surgical technique to reduce blood loss. some authors recommend that these branches should be ligated, but it remains unclear whether these sutures are actually effective in reducing bleeding.this study compared blood loss during cold knife conization of the cervix with and without lateral hemostatic sutures.

this is a study that will evaluate two groups of patients undergoing cold-knife conization for cervical intraepithelial neoplasia high grade where 50% will undergo hemostatic sutures in the lateral cervical and 50% of patients will not be subjected to these sutures. the main objective of the study is to evaluate the amount of intraoperative bleeding.

Eligibility criteria:
inclusion criteria: * indication of cold knife conization exclusion criteria: * conization using techniques other than the cold knife; * previous cervical conization using any other technique; * previous pelvic radiotherapy; * pregnancy; and * refusal to participate in the study

Keywords: cold knife conization lateral hemostatic sutures cervix
physical and chemical study of atherosclerosis mechanisms

Conditions: Myocardial Infarction; Coronary Artery Diseases; Diabetes Mellitus, Type 2; Atherosclerosis of Femoral Artery

Summary: study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.

the chemical and physical properties of different lipids of body. the clinical part of the work is a prospective randomized comparative controlled clinical trial of patients with atherosclerotic diseases. developed the concept of "limited biological resources" of the body based on the increase in the expenditure of energy reserves of the body, allowing a critical look at overweight. the role of overweight in the development of atheromatous fat was revealed. the positive results from the weight loss in patients with atherosclerotic disease were drawn. developed the metabolic concept of atherosclerosis associated with evolutionary aging and conversion of lipids in hard atherosclerotic fat.

Eligibility criteria:
inclusion criteria: * written informed consent form * dyslipidemia (hdl \<1.0 mmol / l, triglycerides (tg) in plasma ≥ 1,7 mmol / l or cholesterol ≥ 5,6 mmol /l) * waist circumference ≥ 94.0 cm in men or ≥ 80,0 cm in women, * bp ≥140/95 mm hg or a patient is taking antihypertensive medications, * fasting glucose ≥ 6,1 mmol / l or the patient is taking hypoglycemic agents, * the possibility of treatment for 6 months and follow-up for 1 year exclusion criteria: * absence of consent form * non-compliance of patient to necessary recommendations. * the presence of mental illness. * complete immobilization of a patient (paresis, and paralysis).

Keywords: atherosclerosis, development of concept, weight loss therapy
local excision in downstaged rectal cancer

Conditions: Rectal Neoplasms

Summary: patients with t2t3 low rectal cancer (size =\< 4 cm) received neoadjuvant treatment (50gy in 5 weeks with concomitant chemotherapy. good responders (residual tumour =\< 2 cm) are randomised in local vs rectal excision, 6-8 weeks after treatment. the composite end point evaluates the rate of patients with death, recurrence, major morbidity or severe after effects at two years.

rectal excision is the standard surgical treatment of rectal cancer. the risk of mortality and major short and long term morbidity induced by rectal excision justifies new treatments. local excision is a conservative alternative approach associated with low mortality and morbidity. the purpose of this prospective randomised multicenter study is to compare local vs rectal excision in good responders after radiochemotherapy for low rectal cancer. patients with t2t3 low rectal cancer, less than 8 cm from the anal verge, size =\< 4 cm, received neoadjuvant treatment, included radiotherapy between 45-55gy in 5 weeks with concomitant chemotherapy consist of at least, one fluoropyrimidine. good clinical responders (residual tumour =\< 2 cm) are randomised in local vs rectal excision, 6-8 weeks after treatment. in case of not confirmed pathological response following local excision, complementary rectal excision is required. bad responders (residual tumour \> 2cm) are treated by primary rectal excision. follow-up includes digital rectal examination, ct-scan and endorectal ultrasound (if local excision) every 4 months for 2 years, then every 6 months for 3 years.

Eligibility criteria:
inclusion criteria: * t2t3 low adenocarcinoma of the rectum * tumour size =\< 4cm * less than 8 cm from the anal verge * no metastatic disease * patient is at least 18 years of age * ecog performance status score =\< 2 * patient and doctor have signed informed consent * inclusion criteria : residual clinical tumour size =\< 2cm after radiochemotherapy exclusion criteria: * t1, t4 tumour or anal sphincter invasion * metastatic disease (m1) * contra indication for radiotherapy and/or fluoropyrimidine use in chemotherapy * history of cancer * symptomatic cardiac or coronary insufficiency * severe renal insufficiency * peripheral neuropathy * patient included in a trial

Keywords: rectal cancer surgery neoadjuvant radiochemotherapy randomized clinical trial multicenter study
efficacy and safety of deoxyspergualin in renal transplant patient with chronic rejection

Conditions: Chronic Rejection

Summary: the purpose of this study to examine the efficacy and safety of cycling treatment of deoxyspergualin in renal transplant patients with biopsy-proven chronic rejection.

the primary aim of this study is to investigate the efficacy of deoxyspergualin after the completion of 6 cycles treatment. the efficacy valuables are histological findings in renal grafts, renal function, proteinuria, graft survival, anti-hla antibody. the safety data are also evaluated in the study.

Eligibility criteria:
inclusion criteria: * chronic rejection defined by banff 2007 criteria exclusion criteria: * patients who have recurrent renal diseases and virus-associated renal diseases * patients who have initial wbc \< 4,000, neutrophil \< 1,000 , platelet \< 50,000 or hb \< 8g * patients who have acute or chronic infection

Keywords: chronic rejection kidney transplantation immunosuppressive
exploratory study of raised serum lactate as a marker of necrotizing fasciitis

Conditions: Fasciitis, Necrotizing

Summary: the investigators examined the hypothesis that serum lactate is raised in early necrotizing fasciitis to a much greater extent than in other differential diagnoses, such as severe cellulitis, and therefore provides a diagnostic indicator.

a prospective comparison of serum lactate levels at referral to the plastic surgery team to the 'gold standard' test of histology at initial surgical debridement, looking at 53 consecutive patients referred with suspected necrotizing fasciitis to a single surgeon at one institution between 2000 and 2010.

Eligibility criteria:
inclusion criteria: * referral to one consultant (mr a armstrong) at one institution (wexham park hospital) with a suspected diagnosis of necrotizing fasciitis between september 2000 and september 2010 exclusion criteria: * nil

Keywords: necrotizing fasciitis fournier's gangrene cellulitis serum lactate